GSK plc (NYSE:GSK) Shares Purchased by Grantham Mayo Van Otterloo & Co. LLC

Grantham Mayo Van Otterloo & Co. LLC lifted its stake in GSK plc (NYSE:GSK - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,153,616 shares of the pharmaceutical company's stock after purchasing an additional 446,568 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC owned about 0.20% of GSK worth $140,475,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Oarsman Capital Inc. lifted its stake in GSK by 28.6% in the fourth quarter. Oarsman Capital Inc. now owns 6,528 shares of the pharmaceutical company's stock worth $221,000 after purchasing an additional 1,450 shares during the last quarter. Provident Investment Management Inc. lifted its stake in shares of GSK by 16.7% during the 4th quarter. Provident Investment Management Inc. now owns 21,675 shares of the pharmaceutical company's stock worth $733,000 after acquiring an additional 3,100 shares during the last quarter. Yoffe Investment Management LLC purchased a new position in GSK during the 4th quarter valued at $462,000. Huber Capital Management LLC increased its stake in GSK by 40.6% in the fourth quarter. Huber Capital Management LLC now owns 6,929 shares of the pharmaceutical company's stock worth $234,000 after purchasing an additional 2,001 shares during the period. Finally, Pitcairn Co. lifted its position in shares of GSK by 22.6% during the fourth quarter. Pitcairn Co. now owns 9,928 shares of the pharmaceutical company's stock worth $336,000 after purchasing an additional 1,828 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

Remove Ads

GSK Price Performance

GSK stock traded down $0.83 during trading on Thursday, hitting $33.66. The stock had a trading volume of 4,760,542 shares, compared to its average volume of 4,591,545. The company's 50-day moving average price is $37.55 and its two-hundred day moving average price is $36.34. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93. The stock has a market capitalization of $69.66 billion, a P/E ratio of 21.21, a PEG ratio of 1.12 and a beta of 0.56. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.67%. The ex-dividend date of this dividend is Friday, February 21st. GSK's dividend payout ratio (DPR) is currently 98.74%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research reports. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, GSK has an average rating of "Moderate Buy" and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.